UNCOVERED: Humacyte - Caught on Camera

Lab-Grown Blood Vessel Got Women on Dialysis Off Catheters Months Sooner Than Fistulas in Interim Phase 3 Data

Interim Phase 3 results from 80 women suggest Humacyte's lab-grown blood vessel provided usable dialysis access sooner than fistulas, reducing catheter time, though independent review is still pending.

Medical Daily · Oct 28

Humacyte Q1 Earnings Call Highlights

Humacyte (NASDAQ:HUMA) reported first-quarter 2026 Symvess sales of $0.5 million and outlined a series of commercial, clinical and cost-reduction initiatives aimed at accelerating adoption of its bioengineered vascular products. On the company’s earnings call, President and Chief Executive Officer

MarketBeat · May 13

Microchip Technology, Tesla, Humacyte And Other Big Stocks Moving Higher On Tuesday

U.S. stocks were mixed, with the Dow Jones index falling over 100 points on Tuesday.

Benzinga · Jul 8, 2025

Humacyte Posts Preclinical Data Of Small-Diameter Human Acellular Vessel In Bypass Grafting

Humacyte Inc (NASDAQ: HUMA) has announced 

Benzinga · Jan 28, 2022